Literature DB >> 24397825

Novel RNA interference-based therapies for sepsis.

Verbena Y Kosovrasti1, Dmitriy Lukashev, Lubomir V Nechev, Mansoor M Amiji.   

Abstract

INTRODUCTION: Sepsis is an extremely fast-paced disease, initiated by an infection that can progress to multiple organ dysfunction and death. The complexity associated with sepsis makes the therapies difficult to develop. Moreover, the 'one-fits-all' kind of therapy is far from being realistic. AREAS COVERED: This review provides a conspectus of the current results of sepsis therapies and their benefits, focusing on the development of small interfering RNA (siRNA) therapeutics for targeting immune cells and sepsis pathways. EXPERT OPINION: The question, 'When will an effective therapy for sepsis be available for patients?' remains unanswered. New RNA interference-mediated therapies are emerging as novel approaches for the treatment of sepsis by downregulating key inflammatory cytokine expression. Strategies that exploit multimodal gene silencing using siRNA and targeted delivery systems are discussed in this review. Some of these strategies have shown positive results in preclinical model of sepsis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24397825     DOI: 10.1517/14712598.2014.875524

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  2 in total

1.  Stealth oxime ether lipid vesicles promote delivery of functional DsiRNA in human lung cancer A549 tumor bearing mouse xenografts.

Authors:  Anu Puri; Faisal Ibrahim; André O'Reilly Beringhs; Camryn Isemann; Paul Zakrevsky; Abigail Whittenburg; Derek Hargrove; Tapan Kanai; Rebecca S Dillard; Natalia de Val; Michael H Nantz; Xiuling Lu; Bruce A Shapiro
Journal:  Nanomedicine       Date:  2022-06-04       Impact factor: 6.096

Review 2.  Melatonin plays critical role in mesenchymal stem cell-based regenerative medicine in vitro and in vivo.

Authors:  Chenxia Hu; Lanjuan Li
Journal:  Stem Cell Res Ther       Date:  2019-01-11       Impact factor: 6.832

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.